Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a research note issued to investors on Sunday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

NASDAQ:LPCN opened at $3.28 on Friday. The firm has a market cap of $17.55 million, a price-to-earnings ratio of -4.32 and a beta of 1.42. Lipocine has a 52 week low of $2.91 and a 52 week high of $11.79. The firm’s 50-day simple moving average is $3.68 and its 200 day simple moving average is $4.52.

Hedge Funds Weigh In On Lipocine

An institutional investor recently raised its position in Lipocine stock. Geode Capital Management LLC increased its stake in Lipocine Inc. (NASDAQ:LPCN) by 6.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.